Ascendis Pharma A/S(ASND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ASND Ascendis Pharma A/S

Market Closed 01-03 16:00:00 EST

140.40

+2.40

+1.74%

盘后140.40

+0.000.00%

16:00 EST

High140.99	Low137.50	Vol314.49K
Open137.50	D1 Closing138.00	Amplitude2.53%
Mkt Cap8.39B	Tradable Cap8.33B	Total Shares59.76M
T/O44.02M	T/O Rate0.53%	Tradable Shares59.32M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ASND","market":"US","secType":"STK","nameCN":"Ascendis Pharma A/S","latestPrice":140.4,"timestamp":1735938000000,"preClose":138,"halted":0,"volume":314489,"hourTrading":{"tag":"盘后","latestPrice":140.4,"preClose":140.4,"latestTime":"16:00 EST","volume":2494,"amount":350157.6,"timestamp":1735938012079},"delay":0,"floatShares":59319788,"shares":59760414,"eps":-8.333144,"marketStatus":"Market Closed","change":2.4,"latestTime":"01-03 16:00:00 EST","open":137.5,"high":140.99,"low":137.5,"amount":44019707.07086,"amplitude":0.02529,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-8.333144,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1736154000000},"marketStatusCode":7,"adr":1,"adrRate":1,"listingDate":1422421200000,"exchange":"NASDAQ","adjPreClose":138,"preHourTrading":{"tag":"盘前","latestPrice":138.1,"preClose":138,"latestTime":"09:25 EST","volume":11,"amount":1529.66011,"timestamp":1735914300090},"postHourTrading":{"tag":"盘后","latestPrice":140.4,"preClose":140.4,"latestTime":"16:00 EST","volume":2494,"amount":350157.6,"timestamp":1735938012079},"volumeRatio":1.520538380322578,"impliedVol":0.4501,"impliedVolPercentile":0.3056},"requestUrl":"/m/hq/s/ASND/tweets","defaultTab":"tweets","newsList":[{"id":"2500925099","title":"Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Ascendis Pharma (ASND) and BioNTech SE (BNTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2500925099","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500925099?lang=en_us&edition=fundamental","pubTime":"2025-01-02 21:10","pubTimestamp":1735823446,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Pharvaris (PHVS – Research Report), Ascendis Pharma (ASND – Resea...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-pharvaris-phvs-ascendis-pharma-asnd-and-biontech-se-bntx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-pharvaris-phvs-ascendis-pharma-asnd-and-biontech-se-bntx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PHVS","BK4551","BK4535","BNTX","BK4585","LU0109394709.USD","BK4137","BK4548","LU0320765992.SGD","LU0889565916.HKD","BK4139","HCSG","BK4007","BK4568","ASND","BK4588"],"gpt_icon":0},{"id":"2495547901","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Axsome Therapeutics (AXSM) and Ascendis Pharma (ASND)","url":"https://stock-news.laohu8.com/highlight/detail?id=2495547901","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495547901?lang=en_us&edition=fundamental","pubTime":"2024-12-30 21:40","pubTimestamp":1735566034,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Axsome Therapeutics (AXSM – Research Report) and Ascendis Pharma ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-axsome-therapeutics-axsm-and-ascendis-pharma-asnd?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-axsome-therapeutics-axsm-and-ascendis-pharma-asnd?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4137","LU0889565916.HKD","BK4007","HCSG","LU0320765992.SGD","AXSM","ASND","BK4585","LU0109394709.USD","BK4139"],"gpt_icon":0},{"id":"2494448230","title":"Leerink Partners Keeps Their Buy Rating on Ascendis Pharma (ASND)","url":"https://stock-news.laohu8.com/highlight/detail?id=2494448230","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494448230?lang=en_us&edition=fundamental","pubTime":"2024-12-25 19:55","pubTimestamp":1735127750,"startTime":"0","endTime":"0","summary":"In a report released on December 23, Joseph Schwartz from Leerink Partners maintained a Buy rating on Ascendis Pharma (ASND – Research Report), wit...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/leerink-partners-keeps-their-buy-rating-on-ascendis-pharma-asnd?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/leerink-partners-keeps-their-buy-rating-on-ascendis-pharma-asnd?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ASND"],"gpt_icon":0},{"id":"2493476480","title":"Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains?","url":"https://stock-news.laohu8.com/highlight/detail?id=2493476480","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493476480?lang=en_us&edition=fundamental","pubTime":"2024-12-23 21:46","pubTimestamp":1734961560,"startTime":"0","endTime":"0","summary":"Sage Therapeutics, Inc.  shares rallied 12.2% in the last trading session to close at $5.61. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 3.1% gain over the past four weeks.The company recently announced a strategic reorganization wherein it decided to focus on the commercialization of its depression drug Zurzuvae , which is marketed in partnership with Biogen. Zurzuvae is the first and only oral treatment indicated for adults with postpartum depression. Sage Therapeutics also anticipates operating expenses to decline in 2025 compared with 2024. This might have driven the recent share price rally.For Sage Therapeutics, the consensus EPS estimate for the quarter has been revised marginally lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on SAGE going for","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ev7Rs1g8mZnA8Zxoa5bA9Q--~B/aD03NTQ7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/72779214019151147f34c8fb2595408d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ev7Rs1g8mZnA8Zxoa5bA9Q--~B/aD03NTQ7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/72779214019151147f34c8fb2595408d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sage-therapeutics-sage-surges-12-134600381.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LU0320765992.SGD","ASND","LU0889565916.HKD","SAGE","BK4585","LU0109394709.USD"],"gpt_icon":0},{"id":"2492173107","title":"Ascendis Pharma announces commercial availability of YORVIPATH in U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2492173107","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492173107?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:41","pubTimestamp":1734615684,"startTime":"0","endTime":"0","summary":"Ascendis Pharma (ASND) announced that YORVIPATH is now commercially available by prescription in the United States. YORVIPATH is a prodrug of parat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-announces-commercial-availability-of-yorvipath-in-u-s?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-announces-commercial-availability-of-yorvipath-in-u-s?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU0109394709.USD","BK4139","LU0889565916.HKD","LU0320765992.SGD","ASND"],"gpt_icon":0},{"id":"2492607843","title":"Ascendis Pharma a/S : Jefferies Raises Target Price to $194 From $191","url":"https://stock-news.laohu8.com/highlight/detail?id=2492607843","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492607843?lang=en_us&edition=fundamental","pubTime":"2024-12-17 13:11","pubTimestamp":1734412274,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nFWN3NI006:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","LU0320765992.SGD","LU0889565916.HKD","LU0109394709.USD","ASND","BK4139"],"gpt_icon":0},{"id":"2492677914","title":"Ascendis Pharma (ASND) Gets a Buy from Stifel Nicolaus","url":"https://stock-news.laohu8.com/highlight/detail?id=2492677914","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492677914?lang=en_us&edition=fundamental","pubTime":"2024-12-17 10:05","pubTimestamp":1734401128,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Ascendis Pharma (ASND – Research Report) yesterday and set a price target of $...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/ascendis-pharma-asnd-gets-a-buy-from-stifel-nicolaus?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/ascendis-pharma-asnd-gets-a-buy-from-stifel-nicolaus?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","BK4127","LU0109394709.USD","BK4139","ASND","LU0320765992.SGD","BK4585","CFA","LU0889565916.HKD"],"gpt_icon":0},{"id":"2492648503","title":"Analysts Offer Insights on Healthcare Companies: Larimar Therapeutics (LRMR) and Ascendis Pharma (ASND)","url":"https://stock-news.laohu8.com/highlight/detail?id=2492648503","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492648503?lang=en_us&edition=fundamental","pubTime":"2024-12-17 02:10","pubTimestamp":1734372606,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Larimar Therapeutics (LRMR – Research Report) and As...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-larimar-therapeutics-lrmr-and-ascendis-pharma-asnd?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-larimar-therapeutics-lrmr-and-ascendis-pharma-asnd?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LRMR","HCSG","LU0320765992.SGD","BK4137","LU0889565916.HKD","BK4585","BK4139","ASND","LU0109394709.USD"],"gpt_icon":0},{"id":"2492994616","title":"European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2492994616","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492994616?lang=en_us&edition=fundamental","pubTime":"2024-12-17 00:10","pubTimestamp":1734365429,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts started the week off higher late Monday morning, rising 0.32% to 1,343.34 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical companies argenx  and Grifols , which rose 4.3% and 3.9% respectively. They were followed by medical device maker EDAP TMS  and pharmaceutical company Ascendis Pharma , which increased 3.1% and 2.7% respectively.The decliners from continental Europe were led by biotech firm Evaxion Biotech  and biopharmaceutical company DBV Technologies , which fell 18% and 3.1% respectively. They were followed by biopharmaceutical company Cellectis  and petroleum refiner Equinor , which were down 2.8% and 2.4% respectively.From the UK and Ireland, the gainers were led by biopharmaceutical company Bicycle Therapeutics  and biotech firm Autolus Therapeutics , which advanced 8.6% and 5% respectively. They were followed by biopharmaceutical companies Verona Pharma  a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ASND","BK4107","ARGX","MREO","VRNA","LU0109394709.USD","LU0320765992.SGD","LU0072461881.USD","EVAX","DBVT","EDAP","CLLS","BK4007","LU0162691827.USD","LU0889565916.HKD","AMRN","TRIB","BCYC","BK4162","BK4505","BK4139","BK4585","LU0320765646.SGD","EQNR","LU1829250122.USD","GRFS","BK4082","AFG","LU1162221912.USD","BK4117","PUK","BK4201","BK4588","AUTL","BP"],"gpt_icon":0},{"id":"2491699158","title":"Ascendis Pharma announces results from New InsiGHTS tril of TransCon hGH","url":"https://stock-news.laohu8.com/highlight/detail?id=2491699158","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491699158?lang=en_us&edition=fundamental","pubTime":"2024-12-16 21:50","pubTimestamp":1734357015,"startTime":"0","endTime":"0","summary":"Ascendis Pharma (ASND) announced Week 26 topline results from New InsiGHTS, its Phase 2 randomized, open-label, active-controlled trial in the U.S....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-announces-results-from-new-insights-tril-of-transcon-hgh?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-announces-results-from-new-insights-tril-of-transcon-hgh?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","BK4585","LU0320765992.SGD","ASND","LU0109394709.USD","BK4139"],"gpt_icon":0},{"id":"2491069624","title":"New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26","url":"https://stock-news.laohu8.com/highlight/detail?id=2491069624","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491069624?lang=en_us&edition=fundamental","pubTime":"2024-12-16 21:30","pubTimestamp":1734355800,"startTime":"0","endTime":"0","summary":"- Results for all three TransCon hGH starting dose cohorts, in first clinical trial of an indication outside of growth hormone deficiency, showed a safety and tolerability profile comparable to daily somatropin. - Annualized height velocity was similar at Week 26 in once-weekly TransCon hGH-treated and daily somatropin-treated children. New InsiGHTS randomized and dosed 49 children with Turner syndrome aged 1 to 10 years old into one of four treatment groups 1:1:1:1 – one of three starting doses of TransCon hGH  or an active comparator of daily somatropin with a starting dose of 0.35 mg/kg/week. Doses were individualized based on IGF-1.“Week 26 topline data from the New InsiGHTS Trial showed that once-weekly TransCon hGH provided comparable safety and endocrine benefits to those seen with the established use of daily somatropin in Turner syndrome,” said Jan Mikkelsen, Ascendis Pharma’s President and Chief Executive Officer. “These positive results lay the foundation for our planned bas","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/retQzGwZVFls5gKxcIUw_w--~B/aD03NzY7dz0yMzE3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/5f3a4374ff0a1aa63de2e8188b526ed4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/retQzGwZVFls5gKxcIUw_w--~B/aD03NzY7dz0yMzE3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/5f3a4374ff0a1aa63de2e8188b526ed4"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/insights-trial-transcon-hgh-lonapegsomatropin-133000792.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0109394709.USD","ASND","LU0320765992.SGD","BK4585","LU0889565916.HKD","BK4139"],"gpt_icon":0},{"id":"2491368958","title":"Ascensis Pharma Says FDA Will Review Application for Adult Treatment of Growth Hormone Deficiency","url":"https://stock-news.laohu8.com/highlight/detail?id=2491368958","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491368958?lang=en_us&edition=fundamental","pubTime":"2024-12-13 06:21","pubTimestamp":1734042060,"startTime":"0","endTime":"0","summary":"Ascendis Pharma said the Food & Drug Administration will review an application to expand the use of its drug to treat growth hormone deficiency to adults.The Danish biopharma company on Thursday said the FDA accepted its supplemental biologics application in adult growth hormone deficiency for TransCon hGH, which is marketed as Skytrofa for pediatric patients.\"This marks another step towards achieving our objective to expand Skytrofa's label beyond pediatric GHD and expand its reach to address new groups of patients,\" Ascendis Chief Executive Jan Mikkelsen said.The application is based on results from a trial that compared the efficacy and safety of weekly TransCon hGH with a weekly placebo and daily human growth hormone in adults with growth hormone deficiency.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4585","LU0889565916.HKD","BK4139","ASND","LU0320765992.SGD"],"gpt_icon":0},{"id":"2491357525","title":"Ascendis Pharma's Supplemental BLA for Adult Growth Hormone Deficiency Drug Accepted by FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2491357525","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491357525?lang=en_us&edition=fundamental","pubTime":"2024-12-13 05:42","pubTimestamp":1734039745,"startTime":"0","endTime":"0","summary":"Ascendis Pharma  said its supplemental biologics license application for TransCon hGH as therapy for adult growth hormone deficiency was accepted for review by the US Food and Drug Administration.The FDA has set a July 27 review deadline, the company said Thursday in a statement.The supplemental application is based on the results of a phase 3 trial that evaluated 259 adults with growth hormone deficiency, and TransCon hGH was found to be \"generally safe and well tolerated,\" Ascendis said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0109394709.USD","LU0889565916.HKD","ASND","LU0320765992.SGD","BK4585","BK4139"],"gpt_icon":0},{"id":"2491368998","title":"FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency","url":"https://stock-news.laohu8.com/highlight/detail?id=2491368998","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491368998?lang=en_us&edition=fundamental","pubTime":"2024-12-13 05:01","pubTimestamp":1734037260,"startTime":"0","endTime":"0","summary":"COPENHAGEN, Denmark, Dec. 12, 2024  -- Ascendis Pharma A/S  today announced that the U.S. Food & Drug Administration  has accepted for review its supplemental Biologics License Application  in adult growth hormone deficiency  for TransCon hGH . The FDA set a Prescription Drug User Fee Act  goal date of July 27, 2025.“This marks another step towards achieving our objective to expand SKYTROFA’s label beyond pediatric GHD and expand its reach to address new groups of patients,” said Jan Mikkelsen, Ascendis Pharma’s President and Chief Executive Officer. “Adult GHD is an undertreated condition associated with significant comorbidities and higher annual healthcare costs compared to the 5-10% of patients who receive treatment, indicative of the high unmet need.”About Ascendis Pharma A/SAscendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its cor","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/retQzGwZVFls5gKxcIUw_w--~B/aD03NzY7dz0yMzE3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/5f3a4374ff0a1aa63de2e8188b526ed4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/retQzGwZVFls5gKxcIUw_w--~B/aD03NzY7dz0yMzE3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/5f3a4374ff0a1aa63de2e8188b526ed4"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-accepts-ascendis-pharma-supplemental-210100726.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD","BK4139","BK4585","ASND"],"gpt_icon":0},{"id":"2490620028","title":"European Equities Traded in the US as American Depositary Edge Higher in Wednesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2490620028","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490620028?lang=en_us&edition=fundamental","pubTime":"2024-12-12 00:33","pubTimestamp":1733934829,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were slightly higher late Wednesday morning, rising 0.3% to 1,347.42 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical company Cellectis  and telecommunications company VEON , which rose 0.5% and 1.3% respectively. They were followed by biotech firm BioNTech  and internet browser company Opera , which increased 1.6% and 1.7% respectively.The decliners from continental Europe were led by biopharmaceutical company Genfit  and oil and gas company TotalEnergies , which lost 3.3% and 3.8% respectively. They were followed by pharmaceutical company Ascendis Pharma  and electronics conglomerate Philips , which were down 0.6% and 1.1%, respectively.From the UK and Ireland, the gainers were led by software firm Endava  and financial services company Lloyds Banking Group , which advanced 2.4% and 3.2% respectively. They were followed by education company Pearson  and cruise line ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2237443549.SGD","CUK","GNFT","LU0823431647.USD","LU2237443465.HKD","DAVA.AU","LU2237443622.USD","PHG","BK4107","TTE","BK4201","CLLS","BK4521","LU2237443978.SGD","BK4117","BK4585","LU2129689514.USD","AFG","LU0084288595.USD","LU0320765992.SGD","BK4139","ADAP","BNTX","VEON","BK4111","BK4082","BK4535","LU2129689605.HKD","BK4204","LU2129689431.USD","AUTL","SLN","LU0109394709.USD","LU2237443382.USD","DAVA","BK4007","BK4548","ASND","BK4568","BK4588","LYG","PSO","OPRA","BK4207","BK4134","BK4023","BK4132","AKTX","LU0950373646.USD","LU0648005311.SGD"],"gpt_icon":0},{"id":"2486036782","title":"Morgan Stanley Sticks to Its Hold Rating for Ascendis Pharma (ASND)","url":"https://stock-news.laohu8.com/highlight/detail?id=2486036782","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486036782?lang=en_us&edition=fundamental","pubTime":"2024-11-25 23:27","pubTimestamp":1732548441,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Ascendis Pharma (ASND – Research Report) today and set a price target of $167.00....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/morgan-stanley-sticks-to-its-hold-rating-for-ascendis-pharma-asnd-5?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/morgan-stanley-sticks-to-its-hold-rating-for-ascendis-pharma-asnd-5?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ASND"],"gpt_icon":0},{"id":"2485029812","title":"European Equities Traded in the US as American Depositary Rise in Friday Trading, Up Over 1% for Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2485029812","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485029812?lang=en_us&edition=fundamental","pubTime":"2024-11-23 00:04","pubTimestamp":1732291478,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were trending modestly higher late Friday morning, rising 0.19% to 1,316.54 on the S&P Europe Select ADR Index, which is up approxima","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPRA","BK4585","BK4107","TRIB","BK4588","BK4207","BK4548","TCBP","BBVA","LU2456880835.USD","ING.AU","BK4023","BK4535","SAN","BK4568","SAN.AU","BK4082","GNFT","BDRX","EDAP","BK4007","LU2236285917.USD","BK7505","BK4551","AKTX","BK4521","ING","AMRN","BK7141","SLN","LU0889565916.HKD","LU2462157665.USD","LU1829250122.USD","BK4139","BK7142","ADAP","AZN","AFG","BNTX","LU0109394709.USD","ASND","LU0320765992.SGD","BK4117","LU2417539215.USD"],"gpt_icon":0},{"id":"2484280496","title":"Ascendis Pharma a/S : Citigroup Cuts Target Price to $200 From $207","url":"https://stock-news.laohu8.com/highlight/detail?id=2484280496","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484280496?lang=en_us&edition=fundamental","pubTime":"2024-11-18 19:25","pubTimestamp":1731929105,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nFWN3MP0N1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","LU0109394709.USD","BK4585","LU0320765992.SGD","BK4139","ASND"],"gpt_icon":0},{"id":"2483586359","title":"Ascendis Pharma Is Maintained at Buy by TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2483586359","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483586359?lang=en_us&edition=fundamental","pubTime":"2024-11-16 02:48","pubTimestamp":1731696480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ASND/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 15, 2024 13:48 ET (18:48 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COWN","TD","ASND"],"gpt_icon":0},{"id":"2483098803","title":"European Equities Traded in the US as American Depositary Drop in Friday Trading, Down 2.8% for Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2483098803","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483098803?lang=en_us&edition=fundamental","pubTime":"2024-11-16 00:09","pubTimestamp":1731686983,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were moving lower late Friday morning, declining 0.85% to 1,302.64 on the S&P Europe Select ADR Index, which is down about 2.8% for t","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MREO","BK4207","EVAX","BDRX","ASND","BK7142","BTI.AU","DBVT","BK4588","BNTX","CLLS","AKTX","BCYC","LYG","BK4535","BK4521","LU0889565916.HKD","BK4505","BTI","LU0320765992.SGD","BK4548","BK4585","PUK","SAN.AU","SAN","TCBP","LU0109394709.USD","ARGX","BK4162","BK4139","BK4568","AFG","BK4107","BK4551","BK4075","BK4117","BK4007","BK7062","BBVA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascendispharma.com","stockEarnings":[{"period":"1week","weight":0.0211},{"period":"1month","weight":0.0717},{"period":"3month","weight":-0.0159},{"period":"6month","weight":0.0338},{"period":"1year","weight":0.1338},{"period":"ytd","weight":0.0198}],"compareEarnings":[{"period":"1week","weight":-0.0051},{"period":"1month","weight":-0.0259},{"period":"3month","weight":0.0331},{"period":"6month","weight":0.0673},{"period":"1year","weight":0.2668},{"period":"ytd","weight":0.01}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.","yearOnYearQuotes":[{"month":1,"riseRate":0.7,"avgChangeRate":0.035453},{"month":2,"riseRate":0.5,"avgChangeRate":0.037735},{"month":3,"riseRate":0.5,"avgChangeRate":0.039038},{"month":4,"riseRate":0.3,"avgChangeRate":-0.046884},{"month":5,"riseRate":0.4,"avgChangeRate":0.000611},{"month":6,"riseRate":0.6,"avgChangeRate":0.017012},{"month":7,"riseRate":0.6,"avgChangeRate":-0.000153},{"month":8,"riseRate":0.7,"avgChangeRate":0.081464},{"month":9,"riseRate":0.6,"avgChangeRate":0.041437},{"month":10,"riseRate":0.4,"avgChangeRate":-0.012194},{"month":11,"riseRate":0.8,"avgChangeRate":0.046776},{"month":12,"riseRate":0.5,"avgChangeRate":0.04575}],"exchange":"NASDAQ","name":"Ascendis Pharma A/S","nameEN":"Ascendis Pharma A/S"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ascendis Pharma A/S(ASND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Ascendis Pharma A/S(ASND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Ascendis Pharma A/S,ASND,Ascendis Pharma A/S股票,Ascendis Pharma A/S股票老虎,Ascendis Pharma A/S股票老虎国际,Ascendis Pharma A/S行情,Ascendis Pharma A/S股票行情,Ascendis Pharma A/S股价,Ascendis Pharma A/S股市,Ascendis Pharma A/S股票价格,Ascendis Pharma A/S股票交易,Ascendis Pharma A/S股票购买,Ascendis Pharma A/S股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ascendis Pharma A/S(ASND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Ascendis Pharma A/S(ASND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction